TP53 and non-small cell lung carcinoma: Li et al. developed and tested a co-delivery system based on hollow mesoporous silica nanospheres for delivering a proteasome inhibitor, bortezomib (BTZ), and the tumor suppressor gene p53 to treat p53-mutant human non-small cell lung cancer (NSCLC) [110].